Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OR502 alone and with cemiplimab in advanced malignancies
NCT06090266Phase 2Recruiting
- Sponsor
- OncoResponse
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of or502 in solid tumor (advanced stage), cutaneous squamous cell carcinoma (cSCC), ovarian cancer and 2 more (6 arms), sponsored by OncoResponse. Primary endpoints: Dose-limiting Toxicity, Adverse Events and Serious Adverse Events and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
or502
03
Conditions
solid tumor (advanced stage)cutaneous squamous cell carcinoma (cSCC)ovarian cancermelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06090266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090266.